Stock·NYSE·Healthcare
Danaher Corp. (DHR)
- Market cap
- $163.25B
- P/E
- 38.46
- Dividend yield
- 0.65%
- Street target
- $260.00median of 24 analysts
- 52-week range
- $160.93 $242.80
DHR stock forecast today
Where DHR stands today, and what CleaRank Financial AI makes of it.
DHR at a glance
Danaher Corp. (DHR): Buy, 71/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($218.85 and $201.11).
- Insiders Insiders sold $504.4M and made no open-market purchases over the last 18 months.
- Valuation P/E of 38.5 against 31.9 for the Healthcare sector: a premium to peers (+21%).
Figures as of October 30, 2026.
CleaRank Financial AI
DHR earns a Buy rating from CleaRank, with a model score of 71/100.
Trend gives the score its biggest lift: the price is 15.47% above its 200-day average and 6.11% above its 50-day average, and the 50-day average is 8.82% above the 200-day. Valuation pulls hardest in the other direction, with a P/E of 38.46 that is 20.6% above the sector median (a premium to peers) and a P/S of 6.38 that is 87.6% above the sector median. Currently the 50-day average is $218.85 and the 200-day is $201.11, and over the past year the price rose 7.99%.
Only on CleaRank
Figures we compute ourselves from DHR's own price, earnings and insider-filing history. Tap one to see it in context.
DHR stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $232.23 is 6.1% above the 50-day simple moving average of $218.85.Price above its 200-day average ›
The price is 15.5% above the 200-day simple moving average of $201.11.50-day average above the 200-day ›
The 50-day average ($218.85) is 8.8% above the 200-day average ($201.11), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 87% of its 52-week range, between $160.93 and $242.80.
DHR share price
Pick a period: each tab shows how far DHR has moved over it, to the last close.
Today's trading
Where DHR sits inside today's range and its 52-week range.
DHR fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
2/4P/E above the sector median ›
The trailing P/E of 38.46 is 20.6% above the Healthcare median of 31.9.P/S above the sector median ›
The price-to-sales ratio of 6.38 is 87.5% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $4.3B on revenue of $25.6B, a net margin of 16.7%.Pays a dividend ›
The trailing dividend yield is 0.65%, or $1.52 a share a year.
Key statistics
The headline figures for DHR.
As of October 30, 2026, DHR trades at $232.23, with a market value of $163.25B, a P/E ratio of 38.46 and a dividend yield of 0.65%.
What the numbers say
CleaRank Financial AI's reading of DHR's valuation, growth and risks.
On earnings, DHR is valued at 38.46 times, against a median of 31.9 for Healthcare: a premium to peers, with the P/E 20.6% above that median. DHR has a market capitalisation of $163.3B.
Profitability is solid, with a net margin of 16.91% and an operating margin of 21.13%. Return on equity stands at 8.19%, which is above the sector median of 7.3%. On the balance sheet, debt-to-equity is 0.52, and the trailing dividend yield is 0.65%, equal to $1.52 paid per share each year.
DHR's most recent earnings report, dated October 21, 2026, came in ahead of expectations: EPS of $2.11 compared with an estimate of $1.92, a beat of 9.90%. Even so, the share price dropped 1.76% in the following session.
DHR has beaten the EPS estimate in each of its last 2 reports, but the share price dropped in the first session after both of those beats. The earlier of the two, the April 21, 2026 report, beat by 6.19%, and the stock then fell 5.40%, the bigger move of the pair. Analysts see EPS reaching $8.58 this fiscal year, a rise of 10.0%, and $9.31 next year, a rise of 8.5%.
At a P/E of 38.46, which is 20.6% above the sector median, DHR is priced as a premium to peers, so any disappointing results would be judged against a high bar. The price typically moves 1.83% in a day, measured as the 30-day standard deviation of daily returns, and the beta against the S&P 500 is 0.80. Over the last 18 months insiders sold $504.4M of stock and bought none on the open market. Insider sales are often planned in advance or made to cover tax on vesting shares, so they tell less than purchases would.
DHR against the Healthcare sector
How DHR compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: DHR trades at a significant premium to sector peers (+21%), suggesting market expectations for superior growth or market position.
Return vs XLV: Since May 20, 2025, DHR has gained 17.4% against a gain of 37.3% for XLV.
Performance against XLV
DHR and the Healthcare sector fund over the same days.
Revenue and earnings
How much DHR sells, and how much of it becomes profit.
The quarterly bars end with Q2 '26 (the quarter to June 30, 2026); DHR reported again on October 21, 2026, and that quarter is not in our statement data yet. The 12-month figures come from the statistics feed and may include it.
Revenue growth: Revenue grew 2.9% in FY2025 to $24.6B, from $23.9B a year earlier.
Profit margin: The net margin was 14.7% in FY2025, down from 16.3% the year before.
Profitable: DHR earned $3.6B in FY2025.
Earnings reality check
Did DHR beat what analysts expected, and how did the stock react?
Earnings record: DHR beat the analyst estimate in 2 of the last 2 quarters.
Market reaction: The stock fell in the first session after 2 of those 2 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 21, 2026after close | $1.92 | $2.11 | +9.90% | -1.76% | +0.09% |
| Apr 21, 2026after close | $1.94 | $2.06 | +6.19% | -5.40% | -8.00% |
As of October 30, 2026, DHR has beaten the analyst EPS estimate in 2 of its last 2 reported quarters and fell in the first trading session after 2 of those beats; its latest report, on October 21, 2026, came in 9.90% above the estimate and the stock moved -1.76% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
DHR AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 58.1, in neutral territory.RSI above 50 ›
An RSI of 58.1 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of DHR
The score, the reasoning behind it, and what could move the price next.
Danaher Corp. (DHR) is in an uptrend, with the price of $232.23 standing above both of its key averages: 6.11% above the 50-day average of $218.85 and 15.47% above the 200-day average of $201.11. The stock trades near the top of its 52-week range, 4.35% below the high of $242.80 and 44.30% above the low of $160.93. The 50-day average also sits 8.82% above the 200-day, so the two averages point the same way.
Danaher's price has climbed over several horizons: up 19.10% across the past three months, up 32.59% across six months and up 7.99% across the last year. Momentum is steady rather than stretched, with the 14-day RSI at 58.1, a neutral reading, and the MACD line sitting in positive territory.
Rating reaffirmed ›
Citigroup kept its Buy rating on October 22, 2026.
Source: Analyst action, Citigroup, October 22, 2026
Earnings beat, but the stock fell ›
The October 21, 2026 report beat the EPS estimate by 9.90%, and the share price fell 1.76% in the first session after it.
Source: Earnings report, October 21, 2026
- Keep an eye on the two levels closest to the price: the 52-week high of $242.80 above it and the 20-day EMA of $227.73 below it.
- The 14-day RSI reads 58.1, in the neutral zone, with the MACD line positive; readings above 70 or below 30 mark stretched momentum.
- DHR beat estimates in 2 of its last 2 reports, yet the share price fell 1.76% in the first session after the October 21, 2026 report.
The uptrend rests on DHR staying above its 50-day average at $218.85 and its 200-day average at $201.11; a close below the 50-day would be the first crack in it. On a pullback, the first level the price would meet is the 20-day EMA at $227.73.
The next level above the price is the 52-week high of $242.80. The 14-day RSI reads 58.1, which is in the neutral zone between 40 and 60.
Technical indicators
Momentum and trend for DHR, from its daily closes.
As of October 30, 2026, with DHR at $232.23, its 14-day RSI is 58.1 (neutral territory), its 50-day simple moving average is $218.85 and its 200-day is $201.11.
Calculated by CleaRank on daily closes as of October 30, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What DHR moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 30, 2026, DHR's 1-year correlation of daily returns is +0.40 with S&P 500 (SPY), +0.28 with Nasdaq 100 (QQQ), +0.08 with Bitcoin (BTC) and +0.03 with gold (XAU).
DHR price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
20 of 24 analysts rate it a buy or strong buy, 4 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $260.00 is 12.0% above the price.No more buy ratings than three months ago ›
20 of 24 rate it a buy now, against 22 of 26 three months ago.
DHR Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 22, 2026 | Citigroup | Maintains | Buy |
| Oct 22, 2026 | Barclays | Maintains | Overweight |
| Oct 22, 2026 | JP Morgan | Maintains | Overweight |
| Oct 22, 2026 | TD Cowen | Maintains | Buy |
| Oct 22, 2026 | Stifel | Maintains | Buy |
| Oct 22, 2026 | Baird | Maintains | Outperform |
As of October 30, 2026, 24 Wall Street analysts cover DHR: 20 rate it a buy or strong buy, 4 a hold and 0 a sell or strong sell. Their 12-month price targets range from $205.00 to $310.00. The median DHR price target is $260.00, 12.0% above the price of $232.23.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
DHR trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
DHR trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from DHR's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much DHR tends to move, against the market and on its own.
DHR price history and drawdowns
DHR's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.83% on an average day (30-day standard deviation of daily returns).Not yet recovered from its worst fall ›
The worst fall was 42.0%, from September 2021 to May 2026; the price is still 18.5% below that peak.Most 1-year holds ended higher ›
67% of 1-year holding periods in the last 10 years ended with a gain.Trailed the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $35,100, against $41,607 in the S&P 500 (SPY).
DHR Drawdowns & Recovery
As of October 30, 2026, DHR's worst peak-to-trough fall over the last 10 years with dividends reinvested was -42.0% (September 2021 to May 2026); it is still 18.5% below that peak, and 67% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into DHR in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: DHR trailed the S&P 500 over this period: $35,100 against $41,607.
A $10,000 investment in DHR in October 2016 would be worth about $35,100 today with dividends reinvested, compared with about $41,607 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to DHR, and which have not.
Strongest month, July: an average of +5.92%, up in 8 of 10 years.
Weakest month, February: an average of -3.91%, up in 3 of 10 years.
This month, October: has averaged -2.24%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, DHR's strongest calendar month has been July (average +5.92%, up in 8 of 10 years) and its weakest February (average -3.91%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
DHR stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in DHR, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in DHR today could grow to about $13,932 by 2030 in the base case, with a 90th-percentile outcome near $27,332 and a 10th-percentile outcome around $7,102. The simulation models price only; at today's 0.65% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
DHR Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $324 for DHR by 2030 in the base case, from $232 today (1.4x over 4 years). The 10th-percentile path ends near $165. These are outcomes of a Monte Carlo simulation run on DHR's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $180 | $252 | $353 | |
| 2028 | $170 | $274 | $441 | |
| 2029 | $166 | $298 | $534 | |
| 2030 | $165 | $324 | $635 |
Method: a lognormal simulation of DHR's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
DHR insider trading
What the people running the company have bought and sold.
DHR insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought DHR shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 30, 2026, DHR insiders reported 12 open-market sales worth $504.4M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 21, 2026 | Rainer M Blair
Chief Executive Officer
|
Sell | 58.3K | $12.7M |
| Aug 4, 2026 | Jose-Carlos Gutierrez-Ramos
Officer
|
Grant | 13.5K | - |
| Aug 4, 2026 | Gregory M Milosevich
Officer
|
Grant | 15.4K | - |
| Aug 4, 2026 | Mitchell P Rales
Officer and Director
|
Grant | 500.0K | - |
| Aug 4, 2026 | Steven M Rales
Chairman of the Board
|
Grant | 500.0K | - |
| Aug 4, 2026 | Christopher Paul Riley
Officer
|
Grant | 41.1K | - |
| Jul 15, 2026 | Linda Filler
Director
|
Option | 3.3K | $237.1K |
| Jul 15, 2026 | Elias A Zerhouni
Director
|
Option | 3.3K | $237.1K |
| May 15, 2026 | Feroz Dewan
Director
|
Grant | 680 | - |
| May 15, 2026 | Linda Filler
Director
|
Grant | 680 | - |
| May 15, 2026 | Charles W Lamanna
Director
|
Grant | 680 | - |
| May 15, 2026 | Teri L. List-Stoll
Director
|
Grant | 680 | - |
| May 15, 2026 | A.shane Sanders
Director
|
Grant | 680 | - |
| May 15, 2026 | Alan G Spoon
Director
|
Grant | 680 | - |
| May 15, 2026 | Raymond C Stevens
Director
|
Grant | 680 | - |
| May 15, 2026 | Elias A Zerhouni
Director
|
Grant | 680 | - |
| May 1, 2026 | Alan G Spoon
Director
|
Sell | 1.4K | $237.2K |
| May 1, 2026 | Alan G Spoon
Director
|
Option | 3.3K | $237.1K |
| Feb 27, 2026 | Rainer M Blair
Chief Executive Officer
|
Grant | 17.6K | - |
| Feb 27, 2026 | Christopher Bouda
Officer
|
Grant | 1.2K | - |
| Feb 27, 2026 | Georgeann F. Couchara
Officer
|
Grant | 4.7K | - |
| Feb 27, 2026 | Robert Bradley Gray
Officer
|
Grant | 2.8K | - |
| Feb 27, 2026 | Matthew E. Gugino
Chief Financial Officer
|
Grant | 4.0K | - |
| Feb 27, 2026 | Jose-Carlos Gutierrez-Ramos
Officer
|
Grant | 6.6K | - |
| Feb 27, 2026 | Jonathan B Leiken
Officer
|
Grant | 2.4K | - |
| Feb 27, 2026 | Matthew Mcgrew
Officer
|
Grant | 5.9K | - |
| Feb 27, 2026 | Gregory M Milosevich
Officer
|
Grant | 4.3K | - |
| Feb 27, 2026 | Mitchell P Rales
Officer and Director
|
Grant | 71.6K | - |
| Feb 27, 2026 | Christopher Paul Riley
Officer
|
Grant | 6.2K | - |
| Feb 27, 2026 | Montgomery Julie A Sawyer
Officer
|
Grant | 6.2K | - |
| Feb 19, 2026 | Gregory M Milosevich
Officer
|
Sell | 1.3K | $274.6K |
| Feb 19, 2026 | Gregory M Milosevich
Officer
|
Option | 1.3K | $77.3K |
| Feb 4, 2026 | Rainer M Blair
Chief Executive Officer
|
Grant | 8.5K | - |
| Feb 4, 2026 | Georgeann F. Couchara
Officer
|
Grant | 1.4K | - |
| Feb 4, 2026 | Brian W Ellis
Officer
|
Grant | 1.7K | - |
| Feb 4, 2026 | Jose-Carlos Gutierrez-Ramos
Officer
|
Grant | 1.7K | - |
| Feb 4, 2026 | Matthew Mcgrew
Chief Financial Officer
|
Grant | 2.7K | - |
| Feb 4, 2026 | Gregory M Milosevich
Officer
|
Grant | 679 | - |
| Feb 4, 2026 | Christopher Paul Riley
Officer
|
Grant | 1.0K | - |
| Feb 4, 2026 | Montgomery Julie A Sawyer
Officer
|
Grant | 848 | - |
| Nov 25, 2025 | Mitchell P Rales
Officer and Director
|
Sell | 40.6K | $9.4M |
| Nov 25, 2025 | Mitchell P Rales
Officer and Director
|
Grant | 22.0K | - |
| Nov 18, 2025 | Teri List
Director
|
Sell | 3.3K | $747.0K |
| Nov 18, 2025 | Teri List
Director
|
Option | 3.3K | $237.1K |
| Nov 14, 2025 | Jonathan B Leiken
General Counsel
|
Grant | 10.2K | - |
| Nov 12, 2025 | Mitchell P Rales
Officer and Director
|
Sell | 437.0K | $95.6M |
| Nov 12, 2025 | Brian W Ellis
General Counsel
|
Sell | 21.8K | $4.8M |
| Nov 12, 2025 | Brian W Ellis
General Counsel
|
Option | 21.8K | $1.3M |
| Nov 11, 2025 | Matthew Mcgrew
Chief Financial Officer
|
Sell | 16.2K | $3.5M |
| Nov 11, 2025 | Matthew Mcgrew
Chief Financial Officer
|
Option | 16.2K | $1.0M |
| Nov 10, 2025 | Georgeann F. Couchara
Officer
|
Sell | 5.2K | $1.1M |
| Nov 10, 2025 | Georgeann F. Couchara
Officer
|
Option | 4.2K | $368.5K |
| Oct 31, 2025 | Mitchell P Rales
Officer and Director
|
Sell | 600.0K | $129.6M |
| Aug 22, 2025 | Teri L. List-Stoll
Director
|
Sell | 2.8K | $586.3K |
| Jul 15, 2025 | John T Schwieters
Director
|
Option | 3.9K | $233.1K |
| Jul 15, 2025 | Elias A Zerhouni
Director
|
Option | 3.9K | $233.1K |
| Jul 2, 2025 | Teri List
Director
|
Option | 3.9K | $233.1K |
| May 15, 2025 | Rainer M Blair
Chief Executive Officer
|
Grant | 27.5K | - |
| May 15, 2025 | Feroz Dewan
Director
|
Grant | 577 | - |
| May 15, 2025 | Linda Filler
Director
|
Grant | 577 | - |
| May 15, 2025 | Charles W Lamanna
Director
|
Grant | 577 | - |
| May 15, 2025 | Teri L. List-Stoll
Director
|
Grant | 577 | - |
| May 15, 2025 | Jessica L Mega, M.D.
Director
|
Grant | 577 | - |
| May 15, 2025 | A.shane Sanders
Director
|
Grant | 577 | - |
| May 15, 2025 | John T Schwieters
Director
|
Grant | 577 | - |
| May 15, 2025 | Alan G Spoon
Director
|
Grant | 577 | - |
| May 15, 2025 | Raymond C Stevens
Director
|
Grant | 577 | - |
| May 15, 2025 | Elias A Zerhouni
Director
|
Grant | 577 | - |
| May 12, 2025 | Steven M Rales
Chairman of the Board
|
Sell | 1.3M | $245.9M |
Source: TwelveData, from SEC Form 4 filings
DHR stock forecast: questions people ask
Answered from the figures on this page, as of October 30, 2026.